ANAVEX2-73 for Alzheimer's Disease
(ATTENTION-AD Trial)
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot take tricyclic antidepressants during the trial.
What makes the drug ANAVEX2-73 unique for treating Alzheimer's disease?
What is the purpose of this trial?
This trial is testing a medication called ANAVEX2-73 to see if it is safe and effective. It targets patients who may need new or better treatment options. The study aims to find out if taking this medication regularly can help improve their condition.
Eligibility Criteria
This trial is for those who completed the ANAVEX2-73-AD-004 study, can be outpatients or in assisted living, and have a partner to help with assessments. They must not have severe suicidal thoughts or behaviors recently and women of childbearing age must not be pregnant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily treatment with ANAVEX2-73 to evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants continue to receive ANAVEX2-73 to assess long-term safety and efficacy
Treatment Details
Interventions
- ANAVEX2-73
Find a Clinic Near You
Who Is Running the Clinical Trial?
Anavex Life Sciences Corp.
Lead Sponsor
Anavex Australia Pty Ltd.
Industry Sponsor
Anavex Germany GmbH
Industry Sponsor